In the September issue of The Journal of Nuclear Medicine - JNM: >Peptide Receptor Radionuclide Therapy or Everolimus in Metastatic Neuroendocrine Tumors: The SeqEveRIV Study, a National Study from the French Group of Endocrine Tumors and Endocan–RENATEN Network >Development of a 213Bi-Labeled Pyridyl Benzofuran for Targeted α-Therapy of Amyloid-β Aggregates >State of the Art: Paraplegic Patient with Metastatic Papillary Thyroid Cancer: A Multidisciplinary Approach to Radioactive Iodine Therapy Safety and Efficacy Strategy >Is it really happening? 177Lu-PSMA (R)Evolution in Cancer Care: Is It Really Happening? >...and more! Read the full issue here: https://lnkd.in/eRun5KAz
Society of Nuclear Medicine and Molecular Imaging (SNMMI)
Non-profit Organizations
Reston, VA 15,495 followers
Transforming medicine. Improving lives.
About us
The Society of Nuclear Medicine and Molecular Imaging (SNMMI), headquartered in Reston, VA, is a nonprofit scientific and professional organization that promotes the science, technology and practical application of nuclear medicine and molecular imaging. SNMMI strives to be a leader in unifying, advancing and optimizing molecular imaging, with an ultimate goal of improving human health. With 15,000 members worldwide, SNMMI represents nuclear and molecular imaging professionals, all of whom are committed to the advancement of the field.
- Website
-
http://www.snmmi.org
External link for Society of Nuclear Medicine and Molecular Imaging (SNMMI)
- Industry
- Non-profit Organizations
- Company size
- 11-50 employees
- Headquarters
- Reston, VA
- Type
- Public Company
- Founded
- 1954
- Specialties
- nuclear medicine, molecular imaging, radiology, and nuclear cardiology
Locations
-
Primary
1850 Samuel Morse Dr
Reston, VA 20190, US
Employees at Society of Nuclear Medicine and Molecular Imaging (SNMMI)
-
Sergio Calvo
Global General Manager, Theranostics at GE HealthCare
-
Crystal Botkin, PhD, MPH, CNMT, PET, FSNMMI-TS
-
Lise Borgwardt
Chief Physician M.D. PH.D. at Copenhagen University Hospital, Rigshospitalet
-
Michael Hofman
Director, Prostate Cancer Theranostics and Imaging Centre of Excellence (ProSTIC), Peter Mac
Updates
-
Even before complications from COVID-19, an estimated 13.3 million adults in the United States dealt with smell disorders, with 3.4 million enduring a severe or complete lack of sense of smell. Smell is so vital to our quality of life, and early intervention for smell-related disorders is essential. A new imaging agent may be able to help. Read more in this month’s JNM: https://lnkd.in/dkfAAWmy
-
We're headed for the last weekend of summer, so let's do a #ThrowbackThursday to our Annual Meeting in June. Our full photo album is now out -- see if you can find yourself amidst our packed lectures and bustling exhibit hall. Feel free to download and share photos using #SNMMI24 and tag us Society of Nuclear Medicine and Molecular Imaging (SNMMI) or @snm_mi on Twitter and IG. https://lnkd.in/ebAn3WWt
-
+15
-
SNMMI Value Initiative is launching four 12-month Clinical Nuclear Oncology Fellowships with an anticipated start date is the 2025-2026 Academic Year (institution dependent). Enhance your expertise in radiopharmaceutical therapies and nuclear oncology. Develop skills in dose administration, patient management, and integrate RPT with other cancer therapies. Learn more and apply by September 30, 2024: https://ow.ly/91jQ50T7H0a
-
Neuroblastoma is one of the most common tumors in children, with a survival rate of 70%. Unfortunately, the standard diagnostic scan often requires sedation, as it takes around two hours to generate a clear image. But a new type of PET scan shows great promise: it can be performed without anesthesia or sedation and lowers the amount of radiation exposure. The study’s author calls it “…a big step forward for the children, parents, and the healthcare system in general.” Read the full article in JNM: https://lnkd.in/egpbn7c6
-
SNMMI knows that unpackaging regarding diagnostic radiopharmaceuticals is important to our members. We have submitted comments in response to CMS' CY2025 Outpatient Prospective Payment System (OPPS) Proposed Rule, applauding the agency's proposal and making additional recommendations for greater patient access. Learn more and read our full comments here: https://lnkd.in/e6Bpai-a
-
Ends Tuesday, don't miss out! Hotel deadline to receive SNMMI group rate discount. Stay at the Bethesda North Marriott Hotel and save on room rates if you make your reservation by Tuesday, August 27. https://lnkd.in/eznCg8eJ
-
Join us in Bethesda, MD on Sept 19-21. Learn from the experts. Connect with colleagues. Gain invaluable insights. Explore the latest in radiopharmaceutical therapy. To learn more check out the Therapeutics Conference website. https://lnkd.in/eHK7vXgD
-
Streamlining Collaborations: Study Startups is a workshop that aims to present ways to minimize the site burden, make trial startups more efficient, meet sponsor timelines, and get medications to patients faster. Join us immediately before the 2024 Therapeutics Meeting – the streamlining workshop will be offered at NO CHARGE to attendees. Register here: https://lnkd.in/d44cGzMi Register for the full Therapeutics Conference (while the early bird rate still applies!) here: https://lnkd.in/deCrk_n4
-
SNMMI congratulates Dr. Wenhui Zhou on his acceptance to Academy’s Council of Early Career Investigators in Imaging (CECI²). Dr. Zhou was nominated by SNMMI as a promising leader in the field and is already in leadership positions in national and local organizations, including committee roles for the SNMMI and RSNA. We are excited about the potential of his research to target and manage invasive lobular breast cancer and the opportunities that CECI will bring him.